Drug Profile
F 12167
Latest Information Update: 14 Dec 2006
Price :
$50
*
At a glance
- Originator Pierre Fabre
- Class
- Mechanism of Action DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 16 May 2001 Pierre Fabre has merged with bioMérieux Alliance
- 27 Apr 1999 Preclinical development for Solid tumours in France (Injection)